Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-10-31T03:25:23.089Z Has data issue: false hasContentIssue false
  • English
  • Français

Olanzapine treatment in adolescents with severe conduct disorder

Published online by Cambridge University Press:  16 April 2020

Gabriele Masi ,
Annarita Milone ,
Giovanna Canepa ,
Stefania Millepiedi ,
Maria Mucci  and
Filippo Muratori
Gabriele Masi*
Affiliation:
IRCCS Stella Maris, Scientific Institute of Child Neurology and Psychiatry, Via dei Giacinti 2, 56018, Calambrone (Pisa), Italy
Annarita Milone
Affiliation:
IRCCS Stella Maris, Scientific Institute of Child Neurology and Psychiatry, Via dei Giacinti 2, 56018, Calambrone (Pisa), Italy
Giovanna Canepa
Affiliation:
IRCCS Stella Maris, Scientific Institute of Child Neurology and Psychiatry, Via dei Giacinti 2, 56018, Calambrone (Pisa), Italy
Stefania Millepiedi
Affiliation:
IRCCS Stella Maris, Scientific Institute of Child Neurology and Psychiatry, Via dei Giacinti 2, 56018, Calambrone (Pisa), Italy
Maria Mucci
Affiliation:
IRCCS Stella Maris, Scientific Institute of Child Neurology and Psychiatry, Via dei Giacinti 2, 56018, Calambrone (Pisa), Italy
Filippo Muratori
Affiliation:
IRCCS Stella Maris, Scientific Institute of Child Neurology and Psychiatry, Via dei Giacinti 2, 56018, Calambrone (Pisa), Italy
*
*Corresponding author. Tel.: +39-050-88-6111; fax: +39-050-32-214. E-mail address:gabriele.masi@inpe.unipi.it (G. Masi).
Get access

Abstract

The most severe forms of conduct disorder (CD) are highly stable and disabling disorders, more likely to persist in time and to evolve into disruptive or antisocial behaviors. One crucial issue in the prognosis of these forms of CD is the high resistence to both non-pharmacological and pharmacological treatments, with antipsychotic drugs being frequently used in refractory cases. Aim of this study was: (1) to explore efficacy and tolerability of olanzapine treatment in adolescents with severe CD; (2) to identify predictors of olanzapine treatment outcome. This was a retrospective study, based on clinical records of the first 23 adolescents diagnosed as having a CD, diagnosed with a clinical interview (K-SADS), either pure or with comorbid diagnoses, and treated with olanzapine. All these patients did not respond satisfactorily to non-pharmacological intervention and to adequate dosages of mood stabilizers (lithium and/or valproate). The sample consisted of 16 males and seven females, 16 inpatients and seven outpatients (mean age 13.6 ± 1.9 years, range 11–17.2 years), followed-up for a period ranging from 6 to 12 months (mean 8.8 ± 2.7 months). Outcome measures included the Modified Overt Aggression Scale (MOAS), Clinical Global Impression-Improvement (CGI-I) and Children Global Assessment Scale (CGAS). During the follow-up, all patients were involved in non-pharmacological treatments (psychotherapy, family therapy, or day-hospital group treatments). Based on both an improvement of at least 50% at MOAS and a score 1 or 2 at CGI-I, 14 out of 23 patients (60.9%) were classified as responders at the end of the follow-up. Significant improvement at the last observation was found in MOAS (P < 0.001) and CGAS (P < 0.001) scores. Olanzapine dosage was 8 ± 3.2 mg/day (range 5–20 mg/day). Mean weight gain at the end of the follow-up was 4.6 ± 3 kg. The predictors of a positive treatment response was an impulsive-affective versus controlled-predatory type of aggression. Age at onset of CD and comorbid disorders did not affect treatment response. These preliminary findings suggest that olanzapine may improve behavior in adolescents with severe and treatment-refractory CD and impulsive aggression.

Keywords

OlanzapineAdolescentsConduct disorderAggression
Type
Original article
Information
European Psychiatry , Volume 21 , Issue 1 , January 2006 , pp. 51 - 57
Copyright
Copyright © Elsevier SAS 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aman, MGDe Smedt, GDerivan, ALyons, BFindling, RLRisperidone Disruptive Behavior Study Group: double-blind, placebo controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am. J. Psychiatry 2002;159:1337–1346.CrossRefGoogle Scholar
Bassarath, LMedication strategies in childhood aggression: a review. Can. J. Psychiatry 2003;48:367–373.CrossRefGoogle ScholarPubMed
Biederman, JFaraone, SVChu, MPWozniak, JFurther evidence of a bidirectional overlap between juvenile mania and conduct disorder in children. J. Am. Acad. Child Adolesc. Psychiatry 1999;38:468–476.CrossRefGoogle ScholarPubMed
Biederman, JMick, EWozniak, JMonuteaux, MCGaldo, MFaraone, SVCan a subtype of conduct disorder linked to bipolar disorder be identified? Integration of findings from the Massachussetts General Hospital Pediatric Psychopharmacology Research Program. Biol. Psychiatry 2003;53:938–944.CrossRefGoogle Scholar
Burke, JDLoeber, RBirmaher, BOppositional defiant disorder and conduct disorder: a review of the past 10 years, Part II. J. Am. Acad. Child Adolesc. Psychiatry 2002;41:1275–1293.CrossRefGoogle ScholarPubMed
Campbell, MSmall, AMGreen, WHJennings, SJPerry, RBennet, WG, et al.Behavioral efficacy of haloperidol and lithium carbonate: a comparison in hospitalized aggressive children with conduct disorder. Arch. Gen. Psychiatry 1984;41:650–656.CrossRefGoogle ScholarPubMed
Campbell, MAdams, PBSmall, AMKafantaris, VSilva, RRShell, J, et al.Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J. Am. Acad. Child Adolesc. Psychiatry 1995;34:445–453.CrossRefGoogle ScholarPubMed
Campbell, MArmenteros, JLMalone, RPAdams, PBEisenberg, ZWOverall, JNeuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J. Am. Acad. Child Adolesc. Psychiatry 1997;36:835–843.CrossRefGoogle ScholarPubMed
Capaldi, DMThe co-occurrence of conduct problems and depressive symptoms in early adolescent boys, II: a 2-year follow-up at grade 8. Dev. Psychopathol. 1992;4:125–144.CrossRefGoogle Scholar
Carlson, GALavelle, JBromet, EJMedication treatment in adolescents vs. adults with psychotic mania. J. Child Adolesc. Psychopharmacol. 1999;9:221–231.CrossRefGoogle ScholarPubMed
Carlson, AGBromet, EJSievers, SPhenomenology and outcome of subjects with early- and adult-onset psychotic mania. Am. J. Psychiatry 2000;157:213–219.CrossRefGoogle ScholarPubMed
Cohen, PCohen, JBrook, JAn epidemiological study of disorders in late childhood and adolescence, II: persistence of the disorders. J. Child Psychol. Psychiatry 1993;34:869–877.CrossRefGoogle ScholarPubMed
Connor, DFBeta blockers for aggression: a review of the pediatric experience. J. Child Adolesc. Psychopharmacol. 1993;3:99–114.CrossRefGoogle Scholar
Connor, DFFletcher, KEWood, JSNeuroleptic-related dyskinesias in children and adolescents. J. Clin. Psychiatry 2001;62:967–974.CrossRefGoogle ScholarPubMed
Connor, DFGlatt, SJLopez, IDJackson, DMelloni, RHPsychopharmacology and aggression, I: a meta-analysis of stimulants effects on overt/covert aggression-related behaviors in ADHD. J. Am. Acad. Child Adolesc. Psychiatry 2002;41:253–261.CrossRefGoogle ScholarPubMed
Cueva, JEOverall, JESmall, AMArmenteros, JLPerry, RCampbell, MCarbamazepine in aggressive children with conduct disorder: a double blind and placebo controlled study. J. Am. Acad. Child Adolesc. Psychiatry 1996;35:480–490.CrossRefGoogle ScholarPubMed
Czobor, PVolavka, JSheitman, BLindenmayer, JPCitrome, LMcEvoy, J, et al.Antipsychotic-induced weight gain and therapeutic response: a differential association. J. Clin. Psychopharmacol. 2002;22:244–251.CrossRefGoogle ScholarPubMed
Donovan, SStewart, JNunes, EQuitkin, FMParides, MDaniel, W, et al.Divalproex treatment for youth with explosive temper and mood lability: a double blind placebo controlled crossover design. Am. J. Psychiatry 2000;57:818–820.CrossRefGoogle Scholar
Findling, RLOpen-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. J. Child Adolesc. Psychopharmacol. 1996;6:165–175.CrossRefGoogle Scholar
Findling, RLMcNamara, NKBranicky, LASchluchter, MDLemon, EBlumer, JLA double blind pilot study of risperidone in the treatment of conduct disorder. J. Am. Acad. Child Adolesc. Psychiatry 2000;38:509–516.CrossRefGoogle Scholar
Frazier, JABiederman, JTohen, MFeldman, PDJacobs, TGRote, MA, et al.A prospective, open-label treatment trial for olanzapine monotherapy in children and adolescents with bipolar disorder. J. Child Adolesc. Psychopharmacol. 2001;11:239–250.CrossRefGoogle ScholarPubMed
Gerardin, PCohen, DMazet, PFlament, MFDrug treatment of conduct disorder in young people. Eur. Neuropsychopharmacol. 2002;12:361–370.CrossRefGoogle ScholarPubMed
Guy, WECDEU Assessment Manual for psychopharmacology, Revised. Rockville, MD: US Department of Health, Education and Welfare; 1976.Google Scholar
Hollingshead, ABTwo Factor Index of social position. Unpublished manuscript. New Haven CT: Yale University, Department of Sociology; 1957.Google Scholar
Kafantaris, VCampbell, MPadron-Gayol, MVSmall, AMLocascio, JJRosenberg, CRCarbamazepine in hospitalized aggressive conduct disorder children: an open pilot study. Psychopharmacol. Bull. 1992;28:193–199.Google Scholar
Kaufman, JBirmaher, BBrent, DRao, UFlynn, CMoreci, P, et al.Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J. Am. Acad. Child Adolesc. Psychiatry 1997;36:980–988.CrossRefGoogle ScholarPubMed
Kay, SRWolkenfeld, FMurrill, LMProfiles of aggression among psychiatric patients. I. Nature and prevalence. J. Nerv. Ment. Dis. 1988;176:539–546.CrossRefGoogle ScholarPubMed
Kazdin, AETreatment for aggressive and antisocial children. Child Adolesc. Psychiatr. Clin. N. Am. 2000;9:841–858.CrossRefGoogle ScholarPubMed
Kemph, JPDeVane, CLLevin, CMJarecke, RMiller, RLTreatment of aggressive children with clonidine: results of an open pilot study. J. Am. Acad. Child Adolesc. Psychiatry 1993;32:577–581.CrossRefGoogle ScholarPubMed
Klein, RGAbikoff, HKlass, EGaneles, DSeese, LMPollack, SClinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch. Gen. Psychiatry 1997;54:1073–1080.CrossRefGoogle ScholarPubMed
Kovacs, MPollock, MBipolar disorder and comorbid conduct disorder in childhood and adolescence. J. Am. Acad. Child Adolesc. Psychiatry 1995;34:715–723.CrossRefGoogle ScholarPubMed
Lahey, BBWaldman, IDMcBurnett, KThe development of anisocial behavior: an integrative causal model. J. Child Psychol. Psychiatry 1999;40:669–682.CrossRefGoogle Scholar
Loeber, RBurke, JDLahey, BBWinters, AZera, MOppositional defiant and conduct disorder: a review of the past 10 years, Part I. J. Am. Acad. Child Adolesc. Psychiatry 2000;39:1468–1484.CrossRefGoogle ScholarPubMed
Malone, RPLuebbert, JFDelaney, MAAdams, PBEisenberg, ZWOverall, JENonpharmacological response in hospitalized children with conduct disorder. J. Am. Acad. Child Adolesc. Psychiatry 1997;36:242–247.CrossRefGoogle ScholarPubMed
Malone, RPBennett, DSLuebbert, JFRowan, ABBiesecker, KABlaney, BL, et al.Aggression: classification and treatment response. Psychopharmacol. Bull. 1998;34:41–45.Google ScholarPubMed
Malone, RPDelaney, MASLuebbert, JFCater, JCampbell, MA double blind, placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch. Gen. Psychiatry 2000;57:649–654.CrossRefGoogle ScholarPubMed
Masi, GToni, CPerugi, GTravierso, MCMillepiedi, SMucci, M, et al.Externalizing disorders in consecutively referred children and adolescents with bipolar disorder. Compr. Psychiatry 2003;44:184–189.CrossRefGoogle ScholarPubMed
Masi, GCosenza, AMucci, MBrovedani, PA 3-year naturalistic study of 53 preschool children with pervasive developmental disorder treated with risperidone. J. Clin. Psychiatry 2003;64:1039–1047.CrossRefGoogle ScholarPubMed
Masi, GPerugi, GToni, CMillepiedi, SMucci, MBertini, N, et al.Predictors of treatment non-response on bipolar children and adolescents with manic or mixed episodes. J. Child Adolesc. Psychopharmacol. 2004;14:395–404.CrossRefGoogle ScholarPubMed
Pappadopulos, EMacintyre, JCCrismon, MLDerivan, AFindling, RLMalone, RP, et al.Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J. Am. Acad. Child Adolesc. Psychiatry 2003;42:145–161.CrossRefGoogle ScholarPubMed
Rifkin, AKarajgi, BDicker, RPerl, EBoppana, VHasan, N, et al.Lithium treatment of conduct disorder in adolescents. Am. J. Psychiatry 1997;154:554–555.Google Scholar
Schur, SBSikich, LFindling, RLMalone, RPCrismon, MLDerivan, A, et al.Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I. J. Am. Acad. Child Adolesc. Psychiatry 2003;42:132–144.CrossRefGoogle ScholarPubMed
Shaffer, DGould, MBrasic, JAmbrosini, PFisher, PBird, H, et al.Children’s Global Assessment Scale (CGAS). Arch. Gen. Psychiatry 1983;40:1228–1231.CrossRefGoogle Scholar
Snyder, RTurgay, AAman, MBinder, CFisman, SCarroll, ARisperidone Conduct Study Group. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J. Am. Acad. Child Adolesc. Psychiatry 2002;41:1026–1036.CrossRefGoogle Scholar
Soderstrom, HRastam, MGilberg, CA clinical case series of six extremely aggressive youths treated with olanzapine. Eur. Child Adolesc. Psychiatry 2002;11:138–141.CrossRefGoogle ScholarPubMed
Stein, DJSimeon, DFrenke, MIslam, MNHollander, EAn open trial of valproate in borderline personality disorder. J. Clin. Psychiatry 1995;56:506–510.Google ScholarPubMed
Stigler, KAPotenza, MNPosey, DJMcDougle, CJWeight gain associated with atypical antypsychotic use in children and adolescents: prevalence, clinical relevance, and management. Paediatr. Drugs 2004;6:33–44.CrossRefGoogle Scholar
Tohen, MGoldberg, JFGonzalez-Pinto Arrillaga, AMAzorin, JMVieta, EHardly-Bayle, MC, et al.A 12-week, double-blind comparison of olanzapine vs. haloperidol in the treatment of acute mania. Arch. Gen. Psychiatry 2003;60:1218–1226.CrossRefGoogle ScholarPubMed
Vitiello, BStoff, DMSubtypes of aggression and their relevance into child psychiatry. J. Am. Acad. Child Adolesc. Psychiatry 1997;36:307–315.CrossRefGoogle ScholarPubMed
Vitiello, BBehar, DHunt, JStoff, DRicciuti, ASubtyping aggression in children and adolescents. J. Neuropsychiatry Clin. Neurosci. 1990;2:189–192.Google ScholarPubMed
Yudofsky, SCSilver, JMJackson, WEndicott, JWilliams, DThe Overt Aggression Scale for the objective rating of verbal and physical aggression. Am. J. Psychiatry 1986;143:35–39.Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.